Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Phase 1 Completed 26 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining thalidomide with docetaxel may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining thalidomide with docetaxel in treating patients who have advanced cancer.

Timeline

Start: 2002-07
Primary completion: 2004-12
Completion: 2006-01

Publications

Results Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	10 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	30 mg/m2	Intravenous
Subject	Thalidomide	Other / unclassified	100 mg	Oral

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications